SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD-AVI & His Recombinant Protein, Biotinylated: Product Information
> 85 % as determined by SDS-PAGE.
< 1.0 EU per μg protein as determined by the LAL method.
0.7-1 as determined by the HABA assay.
Measured by its binding ability in a functional ELISA. Immobilized ACE2 Protein, Human, Recombinant (mFc Tag)(10108-H05H) at 2 μg/mL (100 μL/well) can bind SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD-AVI & His Recombinant Protein, Biotinylated (40589-V27B-B), the EC50 of SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD-AVI & His Recombinant Protein, Biotinylated (40589-V27B-B) is 600-900 ng/mL.
A DNA sequence encoding the SARS-CoV-2 (2019-nCoV) Spike Protein (S1+S2 ECD) (YP_009724390.1) (Met1-Pro1213) was expressed with a c-terminal polyhistidine tagged AVI tag at the C-terminus. The purified protein was biotinylated in vitro.
The recombinant SARS-CoV-2 (2019-nCoV) Spike Protein (S1+S2 ECD) consists of 1224 amino acids and predicts a molecular mass of 136.20 kDa.
Lyophilized from sterile 20mM Tris, 300mM NaCl, pH 8.0, 5% glycerol Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature. Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃ Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
Measured by its binding ability in a functional ELISA. Immobilized ACE2 Protein, Human, Recombinant (mFc Tag)(10108-H05H) at 2 μg/mL (100 μL/well) can bind SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD-AVI & His Recombiant Protein, Biotinylated (40589-V27B-B), the EC50 of SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD-AVI & His Recombiant Protein, Biotinylated (40589-V27B-B) is 600-900 ng/mL.
Coronavirus spike Background Information
The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2; DPP4, dipeptidyl peptidase-4; APN, aminopeptidase N; CEACAM, carcinoembryonic antigen-related cell adhesion molecule 1; Sia, sialic acid; O-ac Sia, O-acetylated sialic acid. The spike is essential for both host specificity and viral infectivity. The term 'peplomer' is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. It's been reported that SARS-CoV-2 (COVID-19 coronavirus, 2019-nCoV) can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. The main functions for the Spike protein are summarized as: Mediate receptor binding and membrane fusion; Defines the range of the hosts and specificity of the virus; Main component to bind with the neutralizing antibody; Key target for vaccine design; Can be transmitted between different hosts through gene recombination or mutation of the receptor binding domain (RBD), leading to a higher mortality rate.
Shen S, et al. (2007) Expression, glycosylation, and modification of the spike (S) glycoprotein of SARS CoV. Methods Mol Biol. 379: 127-35.
Du L, et al. (2009) The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 7 (3): 226-36.
Xiao X, et al. (2004) The SARS-CoV S glycoprotein. Cell Mol Life Sci. 61 (19-20): 2428-30.
Successfully added to cart Please enter catalog numberSubmitted successfullyNetwork ErrorPlease enter your company namePlease enter your namePlease enter your emailPlease enter a valid email addressPlease enter some messageNot found.